Israeli biopharmaceutical firm BioLineRx has launched a Phase Ib/II clinical trial (BATTLE) of BL-8040 in combination with Genentech ’s anti-PDL1 immunotherapy atezolizumab (Tecentriq) in patients suffering from acute myeloid leukaemia (AML).

Related Links:

Adding chimeric antigen receptors to T cells (CAR-T), causing them to aggressively target cancer cells, has proven to be a fruitful approach to the treatment of cancer. Like most immunotherapies, it can result in potentially severe side-effects related to excessive immune activation, but it is also quite effective. Treatment of forms of leukemia in particular has produced good results in a large fraction of patients who have trialed the therapy. In the research reported here, scientists extend the chimeric antigen receptor approach to natural killer cells rather than T cells, noting that this may prove to be both safer and…

Source: Fight Aging!Category: Research Authors: Tags: Daily News Source Type: blogs

In this study, w…

Source: Journal of Hematology and OncologyCategory: Hematology Authors: Tags: Letter to the Editor Source Type: research

CONCLUSIONS: This finding suggested the potential application of PD-1 blockade in AML. The present work demonstrated an excellent synergistic tumour therapeutic effect of PD-1 blockade and CTL therapy compared with either treatment alone.
PMID: 29962321 [PubMed – as supplied by publisher]

Source: HematologyCategory: Hematology Tags: Hematology Source Type: research

Antonio Curti

Acute myeloid leukemia (AML) is a disease, which mainly affects the elderly population. Unfortunately, the prognosis of patients aged >65 years is dismal, with 1-year overall survival approaching 10% with conventional therapies. The hypothesis of harnessing the immune system against cancer, including leukemia, has been postulated for a long time, and several clinical attempts have been made in this field. In the last years, we increased our knowledge about the interplay between AML and immune cells, but no major improvement has been translated, up to now, from bench to bedside. However, the…

Source: CancersCategory: Cancer & Oncology Authors: Tags: Review Source Type: research

Acute myeloid leukemia (AML) is a rapidly progressive, poor-prognosis malignancy arising from hematopoietic stem/progenitor cells. The long history of successful use of allogeneic hematopoietic cell transplantation (alloHCT) in AML indicates that this disease is immunoresponsive, leading to optimism that novel immunotherapies such as bispecific antibodies, chimeric antigen receptor T cells, and immune checkpoint inhibitors will generate meaningful disease control. However, emerging data on the immunoevasive tactics employed by AML blasts at diagnosis and at relapse indicate that optimism must be tempered …

Source: Clinical Cancer ResearchCategory: Cancer & Oncology Authors: Tags: Clin Cancer Res Source Type: research

Despite recent advancements in CAR T-cell therapy for the treatment of acute myeloid leukemia (AML), standard chemotherapy is still the mainstay of treatment for most AML patients. Here, Marion Subkle…

Author: VJHemOnc
Added: 06/12/2018

Source: Oncology TubeCategory: Cancer & Oncology Source Type: podcasts

Marion Subklewe, MD, from LMU Hospital Munich, Munich, Germany, discusses several clinical trials in acute myeloid leukemia (AML) that are currently underway, including a Phase I trial investigating M…

Author: VJHemOnc
Added: 06/11/2018

Source: Oncology TubeCategory: Cancer & Oncology Source Type: podcasts

Publication date: 31 May 2018 Source:Cell, Volume 173, Issue 6 Author(s): Miriam Y. Kim, Kyung-Rok Yu, Saad S. Kenderian, Marco Ruella, Shirley Chen, Tae-Hoon Shin, Aisha A. Aljanahi, Daniel Schreeder, Michael Klichinsky, Olga Shestova, Miroslaw S. Kozlowski, Katherine D. Cummins, Xinhe Shan, Maksim Shestov, Adam Bagg, Jennifer J.D. Morrissette, Palak Sekhri, Cicera R. Lazzarotto, Katherine R. Calvo, Douglas B. Kuhns, Robert E. Donahue, Gregory K. Behbehani, Shengdar Q. Tsai, Cynthia E. Dunbar, Saar Gill The absence of cancer-restricted surface markers is a major impediment to antigen-specific immunotherapy using chimeric…

Source: CellCategory: Cytology Source Type: research

Treatment outcomes for acute myeloid leukemia (AML) patients treated with immunotherapy have significantly lagged behind those achieved for acute lymphoblastic leukemia (ALL), and this is due to the f…

Author: VJHemOnc
Added: 05/29/2018

Source: Oncology TubeCategory: Cancer & Oncology Source Type: podcasts

Gemtuzumab ozogamicin is a monoclonal antibody drug for the treatment of acute myeloid leukemia (AML). This drug uses a different strategy to classical chemotherapeutic agents, and the development of …

Author: VJHemOnc
Added: 05/29/2018

Source: Oncology TubeCategory: Cancer & Oncology Source Type: podcasts

Source link


Please enter your comment!
Please enter your name here

Enter Captcha Here : *

Reload Image